
China Turns to A.I. in Information Warfare
One company's internal documents show how it has undertaken influence campaigns in Hong Kong and Taiwan, and collected data on members of Congress and other influential Americans.
While the firm has not mounted a campaign in the United States, American spy agencies have monitored its activity for signs that it might try to influence American elections or political debates, former U.S. officials said.
Artificial intelligence is increasingly the new frontier of espionage and malign influence operations, allowing intelligence services to conduct campaigns far faster, more efficiently and on a larger scale than ever before.
The Chinese government has long struggled to mount information operations targeting other countries, lacking the aggressiveness or effectiveness of Russian intelligence agencies. But U.S. officials and experts say that advances in A.I. could help China overcome its weaknesses.
A new technology can track public debates of interest to the Chinese government, offering the ability to monitor individuals and their arguments as well as broader public sentiment. The technology also has the promise of mass-producing propaganda that can counter shifts in public opinion at home and overseas.
Want all of The Times? Subscribe.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Trump Is Calling for Intel CEO Lip-Bu Tan to Resign. What Does That Mean for INTC Stock?
Intel (INTC) shares are down more than 3% today after the U.S. president demanded that Lip-Bu Tan – the company's chief executive – 'resign immediately.' According to President Donald Trump, Tan is 'highly CONFLICTED' and there is 'no other solution to this problem.' More News from Barchart Supermicro's Earnings Selloff Explained: Should You Buy SMCI Stock Now? Amazon's $36M Bet on Quantum Computing: What Investors Need to Know AMD Stock Slips After Q2 Earnings, But Here's Why It's a Buying Opportunity Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Including today's decline, Intel stock is down nearly 30% versus its year-to-date high set in February. Why Is Trump's Post Negative for Intel Stock? Investors are choosing caution on INTC shares this morning as the president's social media post highlights political and reputational risks tied to the company's leadership. An administrative demand for Tan to resign introduces meaningful uncertainty around corporate governance and strategic continuity. Labeling him as 'highly CONFLICTED' possibly due to ties with China-based businesses raises fears of national security scrutiny, especially amid heightened U.S.-China trade tensions. Earlier this week, Sen. Tom Cotton, R-Ark wrote a letter to the chairman of the Intel board of directors questioning these alleged ties, including to Cadence Design Systems (CDNS), which just plead guilty to violating U.S. export controls. All in all, Trump's comment signals potential regulatory pressure and leadership instability ahead, risks that may further hurt Intel stock in the second half of 2025. INTC Shares Continue to Face Challenges Trump's remarks add to a string of challenges facing Intel shares that made Seaport Global analysts maintained their 'Sell' rating on the semiconductor company last week. According to the investment firm, INTC stock isn't worth owning despite an attractive valuation since it may continue to lose market share to competitors like Advanced Micro Devices (AMD), particularly in high-performance computing and AI-driven workloads. Moreover, a recently announced NEX spinoff adds complexity to INTC's corporate structure. It's more of a defensive move than a growth catalyst, Seaport told clients in its latest research note. Wall Street Sees Significant Upside in Intel Despite several headwinds threatening Intel's stock price recovery, Wall Street hasn't really thrown in the towel on INTC shares yet. While the consensus rating on the semiconductor stock remains at 'Hold' only, the mean target of about $23 indicates potential upside of roughly 17% from here. On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Yahoo
25 minutes ago
- Yahoo
Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly
Eli Lilly reported growth of 172% and 68% for weight loss drug Zepbound and type 2 diabetes (T2D) treatment Mounjaro, respectively, in Q2 2025, though ceded early advantage to Novo Nordisk in the oral glucagon-like receptor agonist (GLP-1RA) arena. Eli Lilly's two tirzepatide drugs, rival to Novo Nordisk's semaglutide, brought in a combined $8.57bn in the quarter, compared to $4.33bn in Q2 2024. Mounjaro led the growth with approximately $5.2bn, while Zepbound generated around $3.4bn. Mounjaro and Zepbound helped drive the US drugmaker's total Q2 revenue to $15.56bn, up 38% from the same period last year. In a conference call, Eli Lilly CEO David Ricks acknowledged the role the two brands played in the company's revenue, highlighting their strong sales and the company's optimism for high-growth ceilings. Eli Lilly now expects full-year revenue between $60bn and $62bn, up from its previous range of $58bn to $61bn. The raise contrasted with rival Novo Nordisk, which reduced its 2025 outlook last week based on headwinds in the GLP-1RA space. However, shares in Lilly dropped 12% after market open to $656.19 following disappointing data published on the same day for oral weight loss candidate orforglipron. The GLP-1RA arena is set for a major juncture amid the potential approval of more patient-friendly oral versions. Both Novo Nordisk and Eli Lilly are developing candidates in this market and vying for an early lead. Results at orforglipron's highest dose, taken once a day, showed a 12.4% (27.3lb) weight loss at 72 weeks. Novo Nordisk's candidate – which was submitted to the US Food and Drug Administration (FDA) for approval in May 2025 – led to a 13.6% average weight loss. However, Lilly has a strong injectable GLP-1RA foundation on which to build. The 68% growth for Mounjaro, sold in the UK and Europe under the same brand name for both diabetes and weight loss, far surpassed that for Novo Nordisk's Ozempic, which only grew 15% in Q2 compared to the same period last year. Wegovy's global sales fared more favourably, growing 75% in Q2. Wegovy, which has been on the market longer than Zepbound, generated just over $16bn more than Lilly's asset. Analysis by GlobalData still forecasts a higher sales ceiling for tirzepatide by 2031 due to the drug's improved efficacy over semaglutide. Pricing discussions with Trump Eli Lilly is part of a wider pharmaceutical industry battling pricing reforms instigated by US President Donald Trump. The administration is seeking to install a most favoured nation pricing model that would match the costs of certain prescription drugs in the country to the lower prices offered in other developed nations. Executives were coy when asked about potential discussions with Trump, with CEO Ricks saying that 'long term it makes sense to rebalance [pricing].' 'We support the administration's position that medical research costs need to be shared more equitably across developed countries,' Ricks commented. Ricks went on to explain that defects in the US pharma market shift costs to patients and increase red tape. In Pfizer's Q2 earnings call, CEO Albert Bourla said it is in 'very active discussions' around drug pricing. He also confirmed that he personally discussed the matter with Trump, following letters to 17 drugmakers – including Eli Lilly – last week calling for price cuts. "Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
25 minutes ago
- Yahoo
GM to import EV batteries from CATL, WSJ reports
(Reuters) -General Motors will import electric vehicle batteries from Chinese battery giant CATL, The Wall Street Journal reported on Thursday. The arrangement is a stopgap for GM as it works to manufacture its own lower-cost batteries made with lithium iron phosphate (LFP) chemistry, the report added. Global automakers are facing stiff competition from Chinese EV makers and a trade war impacting imports of crucial parts, including rare earth materials, which has pushed production costs higher. GM did not immediately respond to a Reuters request for a comment. Crosstown rival Ford is also making battery cells using tech from CATL to help reduce costs on EV batteries. Reuters last year reported that GM was in talks to buy EV batteries that would use technology from CATL.